Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex.
D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D044842:Cullin Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D004264:DNA Topoisomerases, Type I / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019073:HT29 Cells; D006801:Humans; D000077146:Irinotecan; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex; D034741:RNA, Small Interfering / Q000235:genetics; D016196:S Phase / Q000187:drug effects; D025801:Ubiquitin / Q000378:metabolism
C503645:CUL3 protein, human; D018797:Cell Cycle Proteins; D044842:Cullin Proteins; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D034741:RNA, Small Interfering; D025801:Ubiquitin; D000077146:Irinotecan; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin